Sowmya Viswanathan
Overview
Explore the profile of Sowmya Viswanathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Blanc K, Dazzi F, English K, Farge D, Galipeau J, Horwitz E, et al.
Cytotherapy
. 2025 Jan;
PMID: 39864015
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought...
2.
Renesme L, Cobey K, Lalu M, Bubela T, Chinnadurai R, De Vos J, et al.
Cytotherapy
. 2024 Nov;
27(2):146-168.
PMID: 39580717
Background Aims: Despite promising results in pre-clinical studies, mesenchymal stromal cells (MSCs) face significant challenges in clinical translation. A scoping review by our group highlighted two key issues contributing to...
3.
Moon B, Li K, Malic L, Morton K, Shao H, Banh L, et al.
Lab Chip
. 2024 Sep;
24(21):4948-4961.
PMID: 39291591
Transplantable ready-made microvessels have therapeutic potential for tissue regeneration and cell replacement therapy. Inspired by the natural rapid angiogenic sprouting of microvessels , engineered injectable 3D microvessel networks are created...
4.
Ferrari M, Taboni S, Chan H, Townson J, Gualtieri T, Franz L, et al.
Front Bioeng Biotechnol
. 2024 Jul;
12:1353523.
PMID: 39076208
Reconstruction of mandibular bone defects is a surgical challenge, and microvascular reconstruction is the current gold standard. The field of tissue bioengineering has been providing an increasing number of alternative...
5.
Bodenstein D, Siebiger G, Zhao Y, Clasky A, Mukkala A, Beroncal E, et al.
Stem Cell Res Ther
. 2024 May;
15(1):157.
PMID: 38816774
Mitochondrial transplantation and transfer are being explored as therapeutic options in acute and chronic diseases to restore cellular function in injured tissues. To limit potential immune responses and rejection of...
6.
Robb K, Galipeau J, Shi Y, Schuster M, Martin I, Viswanathan S
Cytotherapy
. 2023 Oct;
26(5):413-417.
PMID: 37804284
Mesenchymal stromal cells (MSCs) are promising cell therapy candidates, but their debated efficacy in clinical trials still limits successful adoption. Here, we discuss proceedings from a roundtable session titled "Failure...
7.
Chinnadurai R, Viswanathan S, Moll G
Front Immunol
. 2023 May;
14:1192636.
PMID: 37153609
No abstract available.
8.
Viswanathan S, Le Blanc K, Ciccocioppo R, Dagher G, Filiano A, Galipeau J, et al.
Cytotherapy
. 2023 May;
25(8):803-807.
PMID: 37149800
The rapidly growing field of mesenchymal stromal cell (MSC) basic and translational research requires standardization of terminology and functional characterization. The International Standards Organization's (ISO) Technical Committee (TC) on Biotechnology,...
9.
Copp G, Robb K, Viswanathan S
Cell Mol Immunol
. 2023 Apr;
20(6):626-650.
PMID: 37095295
Osteoarthritis (OA) is a degenerative multifactorial disease with concomitant structural, inflammatory, and metabolic changes that fluctuate in a temporal and patient-specific manner. This complexity has contributed to refractory responses to...
10.
Robb K, Audet J, Gandhi R, Viswanathan S
Front Immunol
. 2022 Dec;
13:972095.
PMID: 36532069
Adipose-derived mesenchymal stromal cells (MSC(AT)) display immunomodulatory and angiogenic properties, but an improved understanding of quantitative critical quality attributes (CQAs) that inform basal MSC(AT) fitness ranges for immunomodulatory and/or angiogenic...